NEW YORK, April 03, 2017 -- Pomerantz LLP announces that a class action lawsuit has been filed against Under Armour, Inc. (“Under Armour” or the “Company”) (NYSE:UA), (NYSE:UAA) and certain of its officers. The class action, filed in United States District Court, District of Maryland, and docketed under 17-cv-00452 is on behalf of a class consisting of investors who purchased or otherwise acquired Under Armour securities, seeking to recover compensable damages caused by defendants’ violations of the Securities Exchange Act of 1934.
If you are a shareholder who purchased Under Armour securities between April 21, 2016 and January 30, 2017, both dates inclusive, you have until April 10, 2017 to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll free, ext. 9980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and number of shares purchased.
[Click here to join this class action]
Under Armour, Inc. develops, markets, and distributes branded performance products for men, women, and youth. The Company designs and sells a broad offering of apparel and accessories made of synthetic microfibers.
The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that the Company’s revenue and profit margins would not be able to withstanding the heavy promotions, high inventory levels and ripple effects of numerous department store closures and bankruptcy of The Sports Authority, even as Under Armour nevertheless purported to be a growth company that would continue to develop and market game-changing products.
Under Armour has historically touted its aspirations to continue growing 20% annually, having set a goal of $7.5 billion in annual revenue by 2018, however overall sales grew just 12% in the fourth quarter of 2016, with revenues in North American only growing 6%, the weakest increase in the past eight years. Despite continued guidance from April 21, 2016 through October 25, 2016, that the Company would maintain its trend of greater than 20% sales growth, none of these statements had any basis in fact and were false when made.
On January 31, 2017, Under Armour revealed its lower-than-anticipated fourth-quarter revenues and announced the unexpected resignation of Chief Financial Officer (“CFO”) Chip Molloy. Roughly $2.7 billion or one fifth of Under Armour's market capitalization disappeared on January 31, 2017 after Under Armour said its quarterly revenue growth dropped more than 20% for the first time in 26 quarters and that it was replacing its CFO after only 13 months.
On this news, Under Armour’s Class A share price fell $7.45, or 25.74%, to close at $21.49, while the Company’s Class C share price fell $5.87, or 23.4%, to close at $19.22 on January 31, 2017.
The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com
CONTACT: Robert S. Willoughby Pomerantz LLP [email protected]


Coca-Cola Shelves Costa Coffee Sale After Low Private Equity Offers
Starlink Internet Remains Active in Iran Despite Nationwide Blackout
AFT Leaves X Over AI-Generated Images of Minors
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s
Nvidia Denies Upfront Payment Requirement for H200 AI Chips Amid China Export Scrutiny
U.S. Government Invests $1 Billion in L3Harris Rocket Motor Business to Secure Missile Supply Chain
Trump Administration Approves Nvidia H200 AI Chip Sales to China Under New Export Rules
Taiwan Issues Arrest Warrant for OnePlus CEO Over Alleged Illegal Recruitment Activities
NYC Nurses Strike Shuts Down 10 Private Hospitals as 15,000 Demand Safer Staffing and Benefits
Trump Weighs Blocking Exxon Investment as Venezuela Deemed “Uninvestable”
Trump Pushes Tech Giants to Absorb AI Data Center Power Costs, Citing Microsoft Changes
Tesla, EEOC Move Toward Mediation in Racial Harassment Lawsuit
U.S. Lawmakers Raise Alarm Over Trump Approval of Nvidia AI Chip Sales to China
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market
Amazon Reviews Supplier Costs as U.S.–China Tariffs Ease
Allegiant to Acquire Sun Country Airlines in $1.5 Billion Deal to Expand U.S. Leisure Travel Network
Rio Tinto–Glencore Talks Spark Pressure on BHP as Copper Fuels Mining Mega Deals 



